Stockscreener 앱 받기
33.71
0.13%
-0.044
시간 외 거래:
34.04
0.334
+0.99%
전일 마감가:
$33.75
열려 있는:
$33.39
하루 거래량:
2.23M
Relative Volume:
1.26
시가총액:
$3.24B
수익:
$47.30M
순이익/손실:
$-225.97M
주가수익비율:
-14.34
EPS:
-2.35
순현금흐름:
$-188.86M
1주 성능:
+5.50%
1개월 성능:
-5.03%
6개월 성능:
-0.31%
1년 성능:
+290.12%
1일 변동 폭
$33.00
$34.31
1주일 범위
$29.78
$34.50
52주 변동 폭
$6.76
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
명칭
Scholar Rock Holding Corp
전화
857-259-3860
주소
301 BINNEY STREET, CAMBRIDGE, MA
SRRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
33.71 | 3.24B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 재개 | Jefferies | Buy |
| 2025-07-30 | 재개 | Raymond James | Strong Buy |
| 2025-07-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-26 | 재확인 | H.C. Wainwright | Buy |
| 2024-10-07 | 재확인 | H.C. Wainwright | Buy |
| 2024-03-28 | 개시 | Raymond James | Strong Buy |
| 2023-10-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Overweight |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-07-12 | 개시 | Truist | Buy |
| 2022-03-23 | 개시 | H.C. Wainwright | Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-03-12 | 개시 | Robert W. Baird | Outperform |
모두보기
Scholar Rock Holding Corp 주식(SRRK)의 최신 뉴스
Scholar Rock (NASDAQ:SRRK) Insider Sells $102,836.51 in Stock - MarketBeat
SRRK: Piper Sandler Maintains Rating but Lowers Price Target | SRRK Stock News - GuruFocus
Another Catalent Indiana delay: Scholar Rock gets CRL for apitegromab - BioWorld MedTech
SRRK: Barclays Maintains 'Overweight' Rating, Lowers Price Targe - GuruFocus
Scholar Rock (NASDAQ:SRRK) Price Target Lowered to $44.00 at Barclays - MarketBeat
Scholar Rock stock price target lowered to $44 at H.C. Wainwright on FDA delay - Investing.com
Leerink Partners lowers Scholar Rock stock price target to $48 on CRL delay - Investing.com
Voya Investment Management LLC Cuts Stock Holdings in Scholar Rock Holding Corporation $SRRK - MarketBeat
FDA issues complete response letter for Scholar Rock’s SMA drug By Investing.com - Investing.com South Africa
Scholar Rock (NASDAQ:SRRK) Shares Gap Down Following Analyst Downgrade - MarketBeat
SRRK: Analyst Maintains Rating but Lowers Price Target to $44 | - GuruFocus
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection - Benzinga
Scholar Rock (NASDAQ:SRRK) Price Target Cut to $44.00 by Analysts at HC Wainwright - MarketBeat
Another Catalent delay: Scholar Rock gets CRL for apitegromab - BioWorld MedTech
Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says - MarketScreener
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues - Stocktwits
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug - inkl
US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall - Reuters
FDA Rejection Sends Scholar Rock (SRRK) Shares Plummeting - GuruFocus
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Scholar Rock Faces FDA Setback on SMA Drug Due to Manufacturing Site Issues - MarketScreener
Scholar Rock stock falls after FDA issues response letter for SMA drug - Investing.com Nigeria
FDA issues complete response letter for Scholar Rock’s SMA drug - Investing.com
US FDA declines to approve Scholar Rock's muscle weakness drug - MarketScreener
FDA Delays First-Ever Muscle-Targeted SMA Treatment: Scholar Rock's Apitegromab Hits Manufacturing Hurdle - Stock Titan
Scholar Rock SMA drug rejected by FDA over manufacturing concerns - Yahoo Finance
Scholar Rock (NASDAQ:SRRK) Now Covered by Barclays - MarketBeat
Scholar Rock (NASDAQ:SRRK) Shares Up 9%What's Next? - MarketBeat
Should you wait for a breakout in Scholar Rock Holding CorporationPortfolio Performance Summary & Expert Verified Movement Alerts - newser.com
Is Scholar Rock Holding Corporation a candidate for recovery playEarnings Risk Summary & High Accuracy Buy Signal Tips - newser.com
Scholar Rock (NASDAQ:SRRK) Coverage Initiated at Barclays - MarketBeat
Can machine learning forecast Scholar Rock Holding Corporation recoveryQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - newser.com
Insider Selling: Scholar Rock (NASDAQ:SRRK) Director Sells 1,006 Shares of Stock - MarketBeat
Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells 3,178 Shares of Stock - MarketBeat
Leerink Partnrs Forecasts Scholar Rock Q3 Earnings - MarketBeat
Full technical analysis of Scholar Rock Holding Corporation stockTrade Risk Assessment & Free Daily Entry Point Trade Alerts - newser.com
Scholar Rock (NASDAQ:SRRK) Trading Down 5%Here's Why - MarketBeat
What to expect from Scholar Rock Holding Corporation in the next 30 daysJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Intech Investment Management LLC Purchases 21,483 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
History Review: Is Scholar Rock Holding Corporation stock a falling knife or bargain buy2025 Short Interest & Real-Time Price Movement Reports - khodrobank.com
Voya Investment Management LLC Cuts Position in Scholar Rock Holding Corporation $SRRK - Defense World
Scholar Rock (NASDAQ:SRRK) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Published on: 2025-09-19 23:11:54 - newser.com
Will Scholar Rock Holding Corporation benefit from macro trendsQuarterly Market Review & Community Supported Trade Ideas - newser.com
Scholar Rock shares close 6% higher after Leerink initiates at outperform - MSN
What machine learning models say about Scholar Rock Holding Corporation2025 Key Highlights & Detailed Earnings Play Alerts - newser.com
Long term hold vs stop loss in Scholar Rock Holding CorporationWall Street Watch & High Accuracy Swing Entry Alerts - newser.com
How moving averages guide Scholar Rock Holding Corporation tradingJuly 2025 Trends & Fast Gaining Stock Strategy Reports - newser.com
Ideas Watch: Can Scholar Rock Holding Corporation disrupt its industry2025 Historical Comparison & Daily Volume Surge Trade Alerts - خودرو بانک
Chart based exit strategy for Scholar Rock Holding Corporation2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Momentum Shift: Is Scholar Rock Holding Corporation stock a good pick for beginners2025 Price Targets & Long-Term Growth Portfolio Plans - خودرو بانک
Scholar Rock Holding Corp (SRRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
2.51%
자본화:
|
볼륨(24시간):